An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital

Completed

• Conditions: Inflammatory Bowel Diseases

• Registration Number: NCT03248024
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or adalimumab), including biosimilars (infliximab biosimilars: Inflectra ™ and Remsima ™) for treating Crohn's desease or ulcerative colitis

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-28
• Primary Completion: 2017-02-07
• Study Completion: 2017-02-07
• Status Verified: 2017-07
• Study First Submitted: 2017-08-09
• Study First Submitted QC: 2017-08-09
• Last Update Submitted: 2017-08-09
• Study First Posted: 2017-08-14
• Last Update Posted: 2017-08-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 119

Inclusion Criteria

1. Patients consulted at the Gastroenterology services of Nancy University Hospital during the period of inclusion
2. Patients over 18 of age the day of consultation
3. Patients treated at least one time by biotherapy during the last 12 months preceeding inclusion
4. Patients with crohn's disease or ulcerative colitis.
5. Patients accepting to respond to the questionnary

Exclusion Criteria

• Age under 18 years , the day of consultation
• Patient that not accept or unable to complete the retrospective questionnary

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective health care consumption	one year	Desease treatment cost individual level data